Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors

Ras-driven tumors are often refractory to conventional therapies. Here we identify a promising targeted therapeutic strategy for two Ras-driven cancers: Nf1-deficient malignancies and KRas/p53-mutant lung cancer. We show that agents that enhance proteotoxic stress, including the HSP90 inhibitor IPI-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: De Raedt, Thomas, Walton, Zandra, Yecies, Jessica L., Li, Danan, Chen, Yimei, Malone, Clare F., Maertens, Ophelia, Jeong, Seung Min, Bronson, Roderick T., Lebleu, Valerie, Kalluri, Raghu, Normant, Emmanuel, Haigis, Marcia C., Manning, Brendan D., Wong, Kwok-Kin, Macleod, Kay F, Cichowski, Karen
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233475/
https://ncbi.nlm.nih.gov/pubmed/21907929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2011.08.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados